We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (5717)12/23/2019 10:01:58 AM
From: richardred  Respond to of 6087
RE-ENZ speculation IMO why ENZ has potential

Roche to pay Sarepta $1B upfront for DMD gene therapy rights

by Nick Paul Taylor |
Dec 23, 2019 4:19am

Sarepta Therapeutics is in line to pocket up to $1.7 billion in regulatory and sales milestones, plus Roche is paying more than $1 billion upfront for the ex-U.S. rights to Sarepta Therapeutics' Duchenne muscular dystrophy (DMD) gene therapy SRP-9001. The deal comes days after Roche advanced its push into gene therapies by closing the takeover of Spark Therapeutics.

Sarepta has linked SRP-9001 to microdystrophin expression levels of up to 96% in early clinical tests, leading it to start a 24-patient placebo-controlled trial that is due to deliver data next year. Coupled to a safety profile that so far makes SRP-9001 look a better prospect than rival gene therapies from Pfizer and Solid Biosciences, the efficacy data have put Sarepta at the forefront of efforts to develop a one-shot treatment for DMD.

That has attracted the attention of Roche. The Swiss drugmaker is set to pay $750 million in cash and $400 million in equity upfront for the ex-U.S. rights to SRP-9001. Sarepta is also in line to pocket up to $1.7 billion in regulatory and sales milestones, plus royalties. Roche will pay half of global clinical development costs, although Sarepta will continue to handle the trials and manufacturing.